Dr. Lorrie Henderson, Ph.D., MBA has been appointed Chief Operating Officer. In this role, Dr. Henderson will work to further the business strategy and increase brand awareness, profitability and shareholder value globally. Dr. Henderson brings over 25 years of leadership experience in the field of Healthcare/Behavioral Health. He earned his bachelor's degree from Florida Atlantic University, his master's degree from Florida International University, a Ph.D. from Barry University in Florida and an MBA, summa cum laude, from Jones International University.

Chase Herschman has been named the Director of Marketing. Herschman's responsibilities include building brand and consumer awareness of the AIR® line of products. A visionary in his own right, Herschman joined AirWare Labs in 2013 after seeking to market his own nasal filter product. He graduated from Indiana University with a degree in Sports Marketing and Management in 2008.

Michael L. Doll, Director of Quality, has been developing successful products and business opportunities for over 30 years. Doll helped developed the initial vision, definition and refinement of the AirWare Labs nasal dilator and has been an integral part of the organization since 2004. He graduated from University of Colorado with a BS in Mechanical Engineering in 1985.

Andy Shore, Director of Social Media, brings extensive social networking and copywriting skill to AirWare Labs. Shore will focus on delivering quality content to AirWare Labs' social media platforms to increase engagement with and awareness of the AIR® brand and product line. He graduated from Indiana University with a degree in Journalism.

"Our new management team demonstrates AirWare Labs' commitment to being an industry-leading organization," said Jeffrey Rassás, President and CEO of AirWare Labs. "With these key additions we are poised to build on the momentum we've created over the past year."

AirWare Labs recently announced a licensing agreement with Breathe Active, LLC that includes a $2 million national television media campaign. AIR™ ALLERGY was selected last month as a 2014 Visionary Award Finalist for the VISION® Consumer Products Conference in Dallas, and in 2013 AirWare Labs announced a national rollout into 7,500 Walgreen's stores.

About AirWare Labs Corporation:

AirWare Labs Corp., publicly traded as (OTCQB: AIRW), provides patented and innovative technology solutions for consumer products that promote better health through breathing and enhanced wellbeing. AirWare Labs' products are marketed under the brand name of AIR®. AIR® products utilize an FDA approved medical grade silicone, molded as an intranasal Air Breathe dilator, to act as the delivery system. This AIR® microstructure enhances normal nasal airflow with every breath -- clinically proven to deliver up to 40% more oxygen.

Some AIR® products are infused with essential oils with unique healing properties including antibacterial and therapeutic defense against airborne allergens, viruses and bacteria. AIR® Allergy and Travel products provide additional defense in the form of an integrated filter media from 3M to remove microscopic particles that carry viruses, allergens and bacteria. Other AIR® specialty products help provide and performance enhancements and relief from congestion, insomnia, headaches, nausea, and snoring. For more product information, please visit: http://www.airwarelabs.com or company information visit: http://airwarelabscorp.com.

Forward-Looking Statement: The statements in this press release regarding any implied or perceived benefits from the release by AirWare Labs Corp. of its AIR ALLERGY™ product are forward-looking statements. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, and the ability to manage and continue growth.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.